Abstract | OBJECTIVES: MATERIALS AND METHODS: We evaluated the angiogenic profile of HNSCC cells from sensitive and resistant cell lines using antibody array. We further examined the role of interleukin-8 (IL-8) in contributing to resistance both in vitro and in vivo, using a loss- and gain-of-function approach. RESULTS: CONCLUSIONS: These results implicate IL-8 in mediating intrinsic resistance to bevacizumab in HNSCC. Hence, co-targeting of VEGF and IL-8 may help overcome resistance and enhance therapeutic efficacy.
|
Authors | Rekha Gyanchandani, Daisuke Sano, Marcus V Ortega Alves, Jonah D Klein, Beth A Knapick, Sanders Oh, Jeffrey N Myers, Seungwon Kim |
Journal | Oral oncology
(Oral Oncol)
Vol. 49
Issue 8
Pg. 761-70
(Aug 2013)
ISSN: 1879-0593 [Electronic] England |
PMID | 23623402
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2013 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- DNA Primers
- Interleukin-8
- Bevacizumab
|
Topics |
- Animals
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Base Sequence
- Bevacizumab
- Carcinoma, Squamous Cell
(drug therapy, physiopathology)
- DNA Primers
- Down-Regulation
- Female
- Head and Neck Neoplasms
(drug therapy, physiopathology)
- Humans
- Interleukin-8
(blood, physiology)
- Mice
- Mice, Nude
- Neovascularization, Pathologic
- Up-Regulation
- Xenograft Model Antitumor Assays
|